Oasmia acquires novel cancer project from Karo Pharma

24 October 2016

Oasmia Pharmaceutical (OSM: STO) has entered an agreement with fellow Sweden-based Karo Pharma (KARO: STO) relating to the latter’s promising pre-clinical cancer project KB9520.

Under the terms of the deal, Karo Pharma receives 3,080,000 newly-issued shares as a down payment corresponding to a value of 25 million Swedish kronor ($2.8 million). Additionally, Oasmia will pay Karo Pharma 20% of all future revenues generated by the project for Oasmia. Oasmia will continue the development process and will be responsible for all project expenses.

Following the announcement, Karo Pharma’s shares dropped 5.35% to 35.40 kronor by mid-morning trading today, while Oasmia shot up 14.62% to 9.90 kronor.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK